Perimeter Medical Posts Record Revenue Growth on FDA Approval of AI Breast Cancer Device
Event summary
- Q4 2025 revenue surged 143% YoY to $711K, with full-year revenue hitting $2.3M (up 172% YoY).
- FDA granted PMA approval to Claire™ OCT device in March 2026, combining AI with imaging for breast cancer margin assessment.
- Operating expenses fell 46% YoY in Q4 2025 to $2.5M, narrowing net loss by 42% to $2.0M.
- Company secured $3.56M in December 2025 private placement and canceled 14.47M warrants with Social Capital in March 2026.
The big picture
Perimeter's record revenue growth and FDA approval position it as a leader in AI-enhanced breast cancer surgery tools. The company's ability to reduce operating expenses while expanding its installed base suggests improving unit economics, though sustained profitability remains a challenge. The commercial launch of Claire OCT could validate its technology as a standard of care, but competition and reimbursement dynamics will shape long-term adoption.
What we're watching
- Commercialization Pace
- How quickly Perimeter can scale Claire OCT adoption post-launch in Q2 2026.
- Revenue Diversification
- Whether consumable sales and system leases can sustain growth beyond initial device placements.
- Regulatory Expansion
- The timeline for extending AI-enabled OCT technology into other surgical applications.
Related topics